11:04 AM EDT, 10/30/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Wednesday it has seen "positive" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.

Treatment with the gene therapy candidate resulted in "dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes," the company said.

The candidate drug also showed a "favorable safety profile," the company said.

Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.

The company's shares fell nearly 10% in recent trading.

Price: 8.98, Change: -0.99, Percent Change: -9.93